Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3576
CALL
Argan
AGX
$4.49B
| $378K | ﹤0.01% |
1,000
| – | – |
2026 Q2
1 quarter
|
|
|
3577
PUT
Argan
AGX
$4.49B
| $378K | ﹤0.01% |
1,000
| – | – |
2026 Q2
1 quarter
|
|
3578
Bakkt Inc
BKKT
$183M
| $378K | ﹤0.01% |
48,347
+20,814
| +76% | +$165K |
2024 Q3
8 quarters
|
|
3579
Lineage Cell Therapeutics
LCTX
$286M
| $377K | ﹤0.01% |
394,628
-114,040
| -22% | -$126K |
2022 Q3
16 quarters
|
|
3580
Daily Journal
DJCO
$910M
| $375K | ﹤0.01% |
581
+357
| +159% | +$218K |
2017 Q1
38 quarters
|
|
3581
Wealthfront Corp
WLTH
$1.71B
| $375K | ﹤0.01% |
36,080
+30,389
| +534% | +$290K |
2025 Q4
3 quarters
|
|
3582
Atlanticus Holdings
ATLC
$1.24B
| $374K | ﹤0.01% |
4,275
+3,565
| +502% | +$345K |
2020 Q2
25 quarters
|
|
3583
Orthofix Medical
OFIX
$290M
| $373K | ﹤0.01% |
39,642
+8,882
| +29% | +$91.5K |
2013 Q4
51 quarters
|
|
3584
Willis Lease Finance
WLFC
$989M
| $372K | ﹤0.01% |
7,450
+3,733
| +100% | +$229K |
2022 Q3
16 quarters
|
|
3585
Sempreon, Inc. Common Stock
CASK
$379M
| $371K | ﹤0.01% |
28,020
+6,258
| +29% | +$104K |
2016 Q1
42 quarters
|
|
3586
Kamada
KMDA
$470M
| $371K | ﹤0.01% |
43,882
+32,495
| +285% | +$253K |
2023 Q3
12 quarters
|
|
3587
MediaAlpha
MAX
$876M
| $371K | ﹤0.01% |
38,741
+8,392
| +28% | +$105K |
2022 Q1
18 quarters
|
|
3588
ProShares Short VIX Short-Term Futures ETF
SVXY
$204M
| $371K | ﹤0.01% |
5,810
| – | – |
2021 Q1
22 quarters
|
|
3589
Dynagas LNG Partners
DLNG
$117M
| $370K | ﹤0.01% |
94,729
+29,929
| +46% | +$111K |
2020 Q2
25 quarters
|
|
3590
First Western Financial
MYFW
$303M
| $369K | ﹤0.01% |
12,312
+2,057
| +20% | +$64.9K |
2020 Q2
25 quarters
|
|
3591
Franklin Covey
FC
$171M
| $369K | ﹤0.01% |
21,572
+1,421
| +7% | +$28.3K |
2017 Q1
38 quarters
|
|
3592
Cytek Biosciences
CTKB
$752M
| $368K | ﹤0.01% |
61,729
+42,123
| +215% | +$200K |
2022 Q1
18 quarters
|
|
3593
Fate Therapeutics
FATE
$198M
| $368K | ﹤0.01% |
155,215
-32,774
| -17% | -$84.8K |
2017 Q1
38 quarters
|
|
3594
Superior Group of Companies
SGC
$219M
| $367K | ﹤0.01% |
28,986
+2,695
| +10% | +$34.4K |
2023 Q3
12 quarters
|
|
3595
Allogene Therapeutics
ALLO
$312M
| $365K | ﹤0.01% |
228,375
+8,657
| +4% | +$16.5K |
2018 Q4
31 quarters
|
|
3596
Procore
PCOR
$11.6B
| $365K | ﹤0.01% |
7,062
-2,182,507
| -100% | -$115M |
2022 Q1
18 quarters
|
|
3597
Consensus Cloud Solutions
CCSI
$799M
| $364K | ﹤0.01% |
10,417
+7,935
| +320% | +$293K |
2022 Q1
18 quarters
|
|
3598
Red Violet
RDVT
$1.21B
| $363K | ﹤0.01% |
4,592
-871
| -16% | -$61.5K |
2022 Q2
17 quarters
|
|
3599
PUT
Contineum Therapeutics
CTNM
$424M
| $362K | ﹤0.01% |
+27,000
| New | +$402K |
2026 Q3
0 quarters
|
|
3600
West Bancorporation
WTBA
$521M
| $362K | ﹤0.01% |
12,705
+2,688
| +27% | +$76K |
2016 Q3
40 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.